Residential College | false |
Status | 已發表Published |
Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity | |
Tongkai Chen2; Chuwen Li2; Ye Li2; Xiang Yi1; Ruibing Wang2; Simon Ming-Yuen Lee2; Ying Zheng2 | |
2017-03-22 | |
Source Publication | ACS Applied Materials and Interfaces |
ISSN | 1944-8244 |
Volume | 9Issue:11Pages:9516-9527 |
Abstract | Schisantherin A (SA) is a promising anti-Parkinsonism natural product. However, its poor water solubility and rapid serum clearance impose significant barriers to delivery of SA to the brain. This work aimed to develop SA in a nanoparticle formulation that extended SA circulation in the bloodstream and consequently an increased brain uptake and thus to be potentially efficacious for the treatment of Parkinson’s disease (PD). Spherical SA nanoparticles with a mean particle size of 70 nm were prepared by encapsulating SA into methoxy poly(ethylene glycol)-block-poly(d,l)-lactic-co-glycolic acid (mPEG-PLGA) nanoparticles (SA-NPs) with an encapsulation efficiency of ∼91% and drug loading of ∼28%. The in vitro release of the SA-NPs lasted for 48 h with a sustained-release pattern. Using the Madin-Darby canine kidney (MDCK) cell model, the results showed that first intact nanoparticles carrying hydrophobic dyes were internalized into cells, then the dyes were slowly released within the cells, and last both nanoparticles and free dyes were externalized to the basolateral side of the cell monolayer. Fluorescence resonance energy transfer (FRET) imaging in zebrafish suggested that nanoparticles were gradually dissociated in vivo with time, and nanoparticles maintained intact in the intestine and brain at 2 h post-treatment. When SA-NPs were orally administrated to rats, much higher C and AUC were observed in the plasma than those of the SA suspension. Furthermore, brain delivery of SA was much more effective with SA-NPs than with SA suspension. In addition, the SA-NPs exerted strong neuroprotective effects in zebrafish and cell culture models of PD. The protective effect was partially mediated by the activation of the protein kinase B (Akt)/glycogen synthase kinase-3β (Gsk3β) pathway. In summary, this study provides evidence that small-sized mPEG-PLGA nanoparticles may improve cross-barrier transportation, oral bioavailability, brain uptake, and bioactivity of this Biopharmaceutics Classification System (BCS) Class II compound, SA. |
Keyword | Brain Delivery Cellular Uptake Fluorescence Resonance Energy Transfer (Fret) Mpeg−plga Nanoparticles Oral Bioavailability Schisantherin a |
DOI | 10.1021/acsami.7b01171 |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Science & Technology - Other Topics ; Materials Science |
WOS Subject | NanoScience & Nanotechnologymaterials Science, Multidisciplinary |
WOS ID | WOS:000397478100033 |
Scopus ID | 2-s2.0-85015876611 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | DEPARTMENT OF PHARMACEUTICAL SCIENCES Institute of Chinese Medical Sciences THE STATE KEY LABORATORY OF QUALITY RESEARCH IN CHINESE MEDICINE (UNIVERSITY OF MACAU) |
Corresponding Author | Ying Zheng |
Affiliation | 1.The University of North Carolina at Chapel Hill 2.Universidade de Macau |
First Author Affilication | University of Macau |
Corresponding Author Affilication | University of Macau |
Recommended Citation GB/T 7714 | Tongkai Chen,Chuwen Li,Ye Li,et al. Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity[J]. ACS Applied Materials and Interfaces, 2017, 9(11), 9516-9527. |
APA | Tongkai Chen., Chuwen Li., Ye Li., Xiang Yi., Ruibing Wang., Simon Ming-Yuen Lee., & Ying Zheng (2017). Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity. ACS Applied Materials and Interfaces, 9(11), 9516-9527. |
MLA | Tongkai Chen,et al."Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity".ACS Applied Materials and Interfaces 9.11(2017):9516-9527. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment